No connection

Search Results

BIAF vs INBS

BIAF
bioAffinity Technologies, Inc.
BEARISH
Price
$1.35
Market Cap
$6.1M
Sector
Healthcare
AI Confidence
95%
INBS
Intelligent Bio Solutions Inc.
BEARISH
Price
$2.46
Market Cap
$4.9M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BIAF
--
INBS
--
Forward P/E
BIAF
-2.25
INBS
7.03
P/B Ratio
BIAF
0.52
INBS
0.27
P/S Ratio
BIAF
0.9
INBS
1.37
EV/EBITDA
BIAF
0.09
INBS
-0.5

Profitability

Gross Margin
BIAF
27.86%
INBS
46.21%
Operating Margin
BIAF
-158.56%
INBS
-290.89%
Profit Margin
BIAF
-217.5%
INBS
0.0%
ROE
BIAF
-245.18%
INBS
-150.2%
ROA
BIAF
-71.71%
INBS
-51.17%

Growth

Revenue Growth
BIAF
-38.5%
INBS
47.6%
Earnings Growth
BIAF
--
INBS
--

Financial Health

Debt/Equity
BIAF
0.08
INBS
0.18
Current Ratio
BIAF
3.65
INBS
2.38
Quick Ratio
BIAF
3.44
INBS
2.17

Dividends

Dividend Yield
BIAF
--
INBS
--
Payout Ratio
BIAF
0.0%
INBS
0.0%

AI Verdict

BIAF BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a seemingly healthy Current Ratio of 3.65 and low Debt/Equity of 0.08, the company is deeply unprofitable, with a Profit Margin of -217.50% and ROE of -245.18%. Revenue has collapsed by 38.5% year-over-year, and the stock has lost nearly all value over the past five years, down 99.5%. While the recent 1-month price increase of +9.8% may suggest speculative momentum, fundamentals remain abysmal, and the lack of analyst coverage or target prices underscores minimal market confidence.

Strengths
Strong liquidity position with Current Ratio of 3.65 and Quick Ratio of 3.44
Low leverage with Debt/Equity ratio of only 0.08
Positive gross margin of 27.86%, indicating some pricing power or cost control at production level
Risks
Critically low Piotroski F-Score of 1/9 signals high risk of financial failure
Massive and sustained profitability deficits: Operating Margin of -158.56%, ROA of -71.71%
Revenue declining sharply by 38.5% year-over-year, indicating deteriorating business fundamentals
INBS BEARISH

The company exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health. While revenue growth is strong at 47.6% and the balance sheet shows low debt (D/E 0.18), these are overshadowed by an operating margin of -290.89% and a total collapse in share price, which is currently at its 52-week low. The stock is in a clear technical downtrend with a 1-year return of -79.8%, suggesting a lack of investor confidence despite the low Price-to-Book ratio.

Strengths
Strong YoY revenue growth of 47.60%
Low Debt-to-Equity ratio (0.18)
Healthy liquidity with a Current Ratio of 2.38
Risks
Critical financial health (Piotroski F-Score 1/9)
Extreme operating losses (Operating Margin -290.89%)
Severe price depreciation (down 79.8% over 1 year)

Compare Another Pair

BIAF vs INBS: Head-to-Head Comparison

This page compares bioAffinity Technologies, Inc. (BIAF) and Intelligent Bio Solutions Inc. (INBS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile